MaxCyte, Inc.
9713 Key West Ave., Suite 400
Rockville
Maryland
20850
United States
Tel: 1-301-944-1700
Fax: 1-301-944-1703
Website: http://www.maxcyte.com/
Email: careers@maxcyte.com
About MaxCyte, Inc.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.
Stock Exchange: Alternative Investment Market
Stock Symbol: MXCT
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.
186 articles with MaxCyte, Inc.
-
MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
2/24/2022
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the fourth quarter and full year of 2021 after the U.S. market close on Tuesday, March 22nd, 2022.
-
MaxCyte to Participate in Upcoming Investor Conferences - Feb 14, 2022
2/14/2022
MaxCyte, Inc. announced Company management will participate in the following virtual investor conferences.
-
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 11, 2022
2/11/2022
MaxCyte, Inc. announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares of MaxCyte’s common stock to eight newly hired employees.
-
MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
2/1/2022
MaxCyte, Inc., a leading provider of enabling platform technologies for ex-vivo cell engineering, announces the signing of a strategic platform license with Intima Bioscience, Inc., a clinical stage biotechnology company developing genetically engineered cell therapies for solid tumor cancer.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
-
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results
1/24/2022
MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, provides a preliminary update on revenue results for the fourth quarter and full year 2021.
-
MaxCyte to Participate in Upcoming Investor Conferences
11/12/2021
MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announced Company management will participate in the following investor conferences.
-
MaxCyte Reports Third Quarter Financial Results
11/10/2021
MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announced third quarter ended September 30, 2021 financial results.
-
MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board
11/3/2021
MaxCyte, Inc. The company today announces that its Board of Directors has appointed Richard Douglas, PhD, as Chair of the Board.
-
Result of AGM
10/29/2021
MaxCyte, Inc. announces that at its Annual General Meeting held on 29th October 2021, all resolutions were duly passed, with the exception of Proposal 2, relating to the approval of the 2021 Equity Incentive Plan.
-
MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
10/28/2021
MaxCyte, Inc. today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.
-
MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021
10/25/2021
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), today announced that it will release financial results for the third quarter of 2021 after the U.S. market close on Wednesday, November 10th, 2021.
-
MaxCyte Set to Join Russell 2000® Index
9/17/2021
MaxCyte, Inc. today announced that it is set to join the Russell 3000® and Russell 2000® indices, effective after the U.S. market opens on September 20, 2021
-
MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections
9/13/2021
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced its financial results for its second quarter and six months ended June 30, 2021.
-
MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021
9/2/2021
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021.
-
MaxCyte Signs Clinical and Commercial License with Sana Biotechnology
8/9/2021
MaxCyte, Inc., a leading provider of cell-engineering platform technologies, announced the signing of a clinical and commercial license with Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines.
-
MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
7/30/2021
MaxCyte, Inc., a leading provider of cell-engineering platform technologies, announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial offering price of US$13.00 per share.
-
MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market - July 26, 2021
7/26/2021
MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announced the commencement of an underwritten offering of 12,000,000 shares of common stock at an expected offering price between $11.50 and $13.50 per share.
-
MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing
7/12/2021
MaxCyte, Inc. announced the public filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed dual listing of its shares of common stock on the Nasdaq Global Market under the symbol "MXCT." As part of the proposed Nasdaq dual listing, MaxCyte is planning a public offering of shares of its common stock in the United States.
-
Financial information in the Form S-1 registration statement and Change to Board of Directors
7/12/2021
MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market.